1. Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme
- Author
-
Qifeng Ji, Qiao Sai, Bang-Le Zhang, Miao Liu, Dao-zhou Liu, Qibing Mei, Ying Cheng, and Si-Yuan Zhou
- Subjects
Pharmaceutical Science ,02 engineering and technology ,urologic and male genital diseases ,Cell membrane ,03 medical and health sciences ,Biomimetics ,Cell Line, Tumor ,CX3CR1 ,Temozolomide ,Tumor Microenvironment ,medicine ,Humans ,CX3CL1 ,Antineoplastic Agents, Alkylating ,030304 developmental biology ,0303 health sciences ,Chemotactic Factors ,Microglia ,urogenital system ,Chemistry ,Chemotaxis ,021001 nanoscience & nanotechnology ,female genital diseases and pregnancy complications ,nervous system diseases ,medicine.anatomical_structure ,Drug Resistance, Neoplasm ,Apoptosis ,Drug delivery ,Cancer research ,Nanoparticles ,Glioblastoma ,0210 nano-technology ,medicine.drug - Abstract
Currently, clinical treatment for temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) is still a difficult problem. The aim of this paper is to set up a new GBM-targeted drug delivery system to treat TMZ-resistant GBM. Zoledronate (ZOL) not only induces apoptosis of TMZ-resistant GBM cells by down-regulation of farnesyl pyrophosphate synthetase (FPPS) but also increases the proportion of M1-type GBM associated macrophages (GAM). Based on chemoattractants secreted by GBM cells, a ZOL loaded nanoparticle coated with microglia cell membrane (ZOL@CNPs) was prepared to deliver ZOL to central nervous system to treat TMZ-resistant GBM. ZOL@CNPs was actively recruited to TMZ-resistant GBM region by CX3CL1/CX3CR1 and CSF-1/CSF-1R signal axis, and the release of ZOL from ZOL@CNPs was triggered by glutathione in GBM cells. ZOL@CNPs inhibited the growth of TMZ-resistant GBM through inducing apoptosis and inhibiting the migration and invasion of TMZ-resistant GBM cells. Besides, the immunosuppressive and hypoxic microenvironment, playing an important role in the growth of TMZ-resistant GBM, was significantly improved by ZOL@CNPs through increasing the proportion of M1-type GAM and blocking the expression of HIF-1α. ZOL@CNPs has a great potential application in the treatment for TMZ-resistant GBM.
- Published
- 2021